Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

Stock Information for Nordicus Partners Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nordicus Partners Corp

NoviThera has initiated the first efficacy animal studies
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.
Orocidin develops novel cGMP manufacturing process in collaboration with Syngene
Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS
Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market
Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors
Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.